GENE ONLINE|News &
Opinion
Blog

2022-07-14| Trials & Approvals

Amazon, Fred Hutchinson Begin Human Trial for Cancer Vaccine

by Joy Lin
Share To

Amazon and Seattle, Washington-based Fred Hutchinson Cancer Center has launched a clinical trial to assess its cancer vaccine in melanoma and breast cancer. Fred Hutchinson will sponsor the FDA-approved Phase 1 trial, in which Amazon is listed as a collaborator, according to a filing

The two are hoping to recruit 20 participants over the age of 18 with late-stage melanoma or hormone receptor positive, HER2- breast cancer that is either metastatic or does not respond to treatment. The trial is expected to be completed in November 2023. 

 

A Neoantigen Peptide Vaccine Against Cancer

 

Amazon and Fred Hutchinson’s investigational treatment is a personalized neoantigen peptide vaccine which uses multiple tumor-specific antigens. When given together with an adjuvant, the vaccine may induce multiple lines of T cells to mount an immune response against the patient’s tumor. 

In the trial, patients will receive the immunostimulant poly ICLC intramuscular once weekly in weeks when no vaccine is given. Patients are given the cancer vaccine once every 4 weeks, 2 weeks after starting poly ICLC. They will also receive Opdivo (nivolumab) every 2 or 4 weeks. The treatment regime will continue for 25 weeks, after which patients are followed up at 24, 36, and 48 weeks. 

Related article: Vaccines Against Cancers May Be the Future 

 

Amazon’s Push Into Healthcare 

 

Amazon has confirmed the partnership to CNBC, and said it will contribute scientific and machine learning expertise to the collaboration. Its cloud technology platform, Amazon Web Services (AWS), has been used by the Fred Hutch Microbiome Research Initiative — funded by Fred Hutchinson — to power a high-performance computing platform for microbiome analysis. Other users of the AWS include Moderna, Philips and the UK NHS.

Amazon has been expanding multilaterally in the healthcare industry, with the 2020 launch of an online pharmacy, as well as efforts to promote its telehealth service called Amazon Care. The company has developed a wearable health tracker called the Halo Band that helps users analyze their sleep, activity, nutrition, and more. Furthermore, the company is also looking to develop at-home diagnostic testing for diseases. 

Last year, the company captured attention when its ex-CEO Jeff Bezos was revealed as an investor in Altos Labs, a startup with the grand ambition to make people younger via anti-aging technology.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Revolutionizing Typhoid Vaccination: Vaxxas Receives US$3.67 Million Grant from Wellcome for Needle-Free Vaccine Patch Clinical Study
2023-08-30
GeneOnline’s Weekly News Highlights: Aug 21-25
2023-08-28
Bavarian Nordic Closes on Valneva in Chikungunya Vaccine Race
2023-08-14
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top